What’s Next With Next-Generation BRAF Inhibitors?ByDavid HowardApril 15th 2014Targeted therapy for patients with activating BRAF mutations has demonstrated the potential for personalized medicine in patients with metastatic melanoma. Initial study results were promising and dramatic.